drugset
drugset / Trial / NCT06155487

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects

NCT06155487 ↗

Phase 1 Enrolling by invitation 68 enrolled JMackem Co., Ltd Seoul National University Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Preliminary evaluate of pharmacokinetics, pharmacodynamics, safety and tolerability after oral administration of AJH-2947 in healthy Korean or Caucasian male subjects

Timeline

Start
2023-12-05
Primary completion
2025-04
Completion
2025-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AJH-2947 Unknown 100 mg Oral
Subject AJH-2947 Unknown 200 mg Oral
Subject AJH-2947 Unknown 300 mg Oral
Subject AJH-2947 Unknown 400 mg Oral
Subject AJH-2947 Unknown 600 mg Oral
Subject AJH-2947 Unknown 800 mg Oral

Indications

diabetic neuropathy neuropathy, painful postherpetic neuralgia